Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2003

View Archived Issues

NN-703 may be effective in adults with moderately severe GH deficiency

Antiviral and spermicidal agent WHI-05 in development

NXC-4720 generates positive data in validation studies

Improved vision in extension phase of Lucentis wet AMD study

Development of AS-1403 discontinued following phase I biodistribution results

Findings from DAC:GLP-1 studies reported

Vical and Merck & Co. amend license agreement

Medtronic to commercialize rhBMP-2 in Japan

Novel telomerase inhibitors covered by Cancer Research Technology patent

New mGluR5 antagonists in early development at Merck

Boehringer Igelheim describes new glucocorticoid receptor modulators and their use

Novel pyridazinone-based p38 kinase inhibitors prepared by Pharmacia researchers

Bayer scientists prepare and test new gamma-secretase inhibitors for AD therapy

DakoCytomation and Northwest Biotherapeutics to develop prostate cancer diagnostics

Zengen drug delivery technology used for oral strip products

Meditech and Elan extend joint venture

Phase II Campath trial in MS makes progress

TZE-5323: a potential therapeutic drug for the long-term treatment of endometriosis

Synthetic progestins with high tissue and receptor selectivity

PHA-927F reported to be a potent and selective inhibitor of tissue factor/factor VIIa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...